Home / Publication / Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

刊物

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Author(s): Alice Ke, Zoe Barter, Karen Rowland-Yeo, Lisa Almond

Year: 2016 年 7 月 20 日

肿瘤领域模型引导的药物开发（MIDD）精要

博客

Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验

事实资料表

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

网络研讨会

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

案例研究

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

肿瘤领域模型引导的药物开发（MIDD）精要

Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

订阅时事通讯

快捷链接

解决方案

联系我们